2015 -- H 5602 | |
======== | |
LC001431 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2015 | |
____________ | |
A N A C T | |
RELATING TO INSURANCE - PRESCRIPTION DRUG BENEFITS | |
| |
Introduced By: Representatives Kennedy, Azzinaro, Keable, Winfield, and Shekarchi | |
Date Introduced: February 25, 2015 | |
Referred To: House Corporations | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness |
2 | Insurance Policies" is hereby amended by adding thereto the following section: |
3 | 27-18-33.2. Pharmacy benefit manager requirements with respect to multi-source |
4 | generic pricing updates to pharmacies. – (a) Definitions. As used herein: |
5 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
6 | manager will pay toward the cost of a drug; |
7 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
8 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
9 | temporarily unavailable; |
10 | (3) "Therapeutically equivalent" means the equivalent determined by the United States |
11 | Food and Drug Administration. |
12 | (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect |
13 | to multi-source generic pricing updates to pharmacies: |
14 | (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts |
15 | between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting |
16 | representative or agent such as a pharmacy services administrative organization (PSAO): |
17 | (i) Include in such contracts, the basis of the methodology and sources utilized to |
18 | determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any |
19 | successive benchmark pricing formula) of the PBM, update such pricing information on such at |
| |
1 | least every seven (7) calendar days, and establish a reasonable process for the prompt notification |
2 | of such pricing updates to network pharmacies; and |
3 | (ii) Maintain a procedure to eliminate products from the list of drugs subject to such |
4 | pricing or modify MAC rates within three (3) days when such drugs do not meet the standards |
5 | and requirements of this act as set forth in order to remain consistent with pricing changes in the |
6 | marketplace. |
7 | (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source |
8 | generic pricing: |
9 | (1) In order to place a particular prescription drug on a multi-source generic list, the PBM |
10 | must, at a minimum, ensure that: |
11 | (i) The drug have at least three (3) or more nationally available, therapeutically |
12 | equivalent, multiple source generic drugs; |
13 | (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated |
14 | by the Food and Drug Administration; and |
15 | (iii) The product must be available for purchase without limitations by all pharmacies in |
16 | the state from national or regional wholesalers, and not obsolete or temporarily unavailable. |
17 | (d) Standards for pharmacy appeals: |
18 | (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a |
19 | pharmacy's contracting representative or agent such as a pharmacy services administrative |
20 | organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding |
21 | multi-source generic drug pricing. The process shall include the following provisions: |
22 | (i) The right to appeal shall be limited to sixty (60) days following the initial claim; |
23 | (ii) The appeal shall be investigated and resolved within seven (7) days; |
24 | (iii) A telephone number at which a network pharmacy may contact the PBM and speak |
25 | with an individual who is responsible for processing appeals; |
26 | (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify |
27 | the national drug code or UDI of a drug product that may be purchased by contracted pharmacies |
28 | at a price at or below the maximum allowable cost (or benchmark price as determined by the |
29 | PBM). |
30 | (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of |
31 | initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated |
32 | pharmacies in this state that are within the network. Any adjustment must be made to all |
33 | pharmacies within five (5) business days. |
34 | (e) The department of business regulation shall exercise oversight and enforcement of |
| LC001431 - Page 2 of 10 |
1 | this section. |
2 | SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service |
3 | Corporations" is hereby amended by adding thereto the following section: |
4 | 27-19-26.1. PBM requirements with respect to multi-source generic pricing updates |
5 | to pharmacies. -- (a) Definitions. As used herein: |
6 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
7 | manager will pay toward the cost of a drug; |
8 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
9 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
10 | temporarily unavailable; |
11 | (3) "Therapeutically equivalent" means the equivalent determined by the United States |
12 | Food and Drug Administration. |
13 | (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect |
14 | to multi-source generic pricing updates to pharmacies. |
15 | (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts |
16 | between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting |
17 | representative or agent such as a pharmacy services administrative organization (PSAO): |
18 | (i) Include in such contracts, the basis of the methodology and sources utilized to |
19 | determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any |
20 | successive benchmark pricing formula) of the PBM, update such pricing information on such at |
21 | least every seven (7) calendar days, and establish a reasonable process for the prompt notification |
22 | of such pricing updates to network pharmacies; and |
23 | (ii) Maintain a procedure to eliminate products from the list of drugs subject to such |
24 | pricing or modify MAC rates within three (3) days when such drugs do not meet the standards |
25 | and requirements of this act as set forth in order to remain consistent with pricing changes in the |
26 | marketplace. |
27 | (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source |
28 | generic pricing: |
29 | (1) In order to place a particular prescription drug on a multi-source generic list, the PBM |
30 | must, at a minimum, ensure that: |
31 | (i) The drug have at least three (3) or more nationally available, therapeutically |
32 | equivalent, multiple source generic drugs; |
33 | (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated |
34 | by the Food and Drug Administration; and |
| LC001431 - Page 3 of 10 |
1 | (iii) The product must be available for purchase without limitations by all pharmacies in |
2 | the state from national or regional wholesalers, and not obsolete or temporarily unavailable. |
3 | (d) Standards for pharmacy appeals: |
4 | (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a |
5 | pharmacy's contracting representative or agent such as a pharmacy services administrative |
6 | organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding |
7 | multi-source generic drug pricing. The process shall include the following provisions: |
8 | (i) The right to appeal shall be limited to sixty (60) days following the initial claim; |
9 | (ii) The appeal shall be investigated and resolved within seven (7) days; |
10 | (iii) A telephone number at which a network pharmacy may contact the PBM and speak |
11 | with an individual who is responsible for processing appeals; |
12 | (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify |
13 | the national drug code or UDI of a drug product that may be purchased by contracted pharmacies |
14 | at a price at or below the maximum allowable cost (or benchmark price as determined by the |
15 | PBM). |
16 | (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of |
17 | initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated |
18 | pharmacies in this state that are within the network. Any adjustment must be made to all |
19 | pharmacies within five (5) business days. |
20 | (e) The department of business regulation shall exercise oversight and enforcement of |
21 | this section. |
22 | SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service |
23 | Corporations" is hereby amended by adding thereto the following section: |
24 | 27-20-23.1. Pharmacy benefit manager requirements with respect to multi-source |
25 | generic pricing updates to pharmacies. -- (a) Definitions. As used herein: |
26 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
27 | manager will pay toward the cost of a drug; |
28 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
29 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
30 | temporarily unavailable; |
31 | (3) "Therapeutically equivalent" means the equivalent determined by the United States |
32 | Food and Drug Administration. |
33 | (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect |
34 | to multi-source generic pricing updates to pharmacies. |
| LC001431 - Page 4 of 10 |
1 | (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts |
2 | between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting |
3 | representative or agent such as a pharmacy services administrative organization (PSAO): |
4 | (i) Include in such contracts, the basis of the methodology and sources utilized to |
5 | determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any |
6 | successive benchmark pricing formula) of the PBM, update such pricing information on such at |
7 | least every seven (7) calendar days, and establish a reasonable process for the prompt notification |
8 | of such pricing updates to network pharmacies; and |
9 | (ii) Maintain a procedure to eliminate products from the list of drugs subject to such |
10 | pricing or modify MAC rates within three (3) days when such drugs do not meet the standards |
11 | and requirements of this act as set forth in order to remain consistent with pricing changes in the |
12 | marketplace. |
13 | (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source |
14 | generic pricing: |
15 | (1) In order to place a particular prescription drug on a multi-source generic list, the PBM |
16 | must, at a minimum, ensure that: |
17 | (i) The drug have at least three (3) or more nationally available, therapeutically |
18 | equivalent, multiple source generic drugs; |
19 | (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated |
20 | by the Food and Drug Administration; and |
21 | (iii) The product must be available for purchase without limitations by all pharmacies in |
22 | the state from national or regional wholesalers, and not obsolete or temporarily unavailable. |
23 | (d) Standards for pharmacy appeals: |
24 | (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a |
25 | pharmacy's contracting representative or agent such as a pharmacy services administrative |
26 | organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding |
27 | multi-source generic drug pricing. The process shall include the following provisions: |
28 | (i) The right to appeal shall be limited to sixty (60) days following the initial claim; |
29 | (ii) The appeal shall be investigated and resolved within seven (7) days; |
30 | (iii) A telephone number at which a network pharmacy may contact the PBM and speak |
31 | with an individual who is responsible for processing appeals; |
32 | (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify |
33 | the national drug code or UDI of a drug product that may be purchased by contracted pharmacies |
34 | at a price at or below the maximum allowable cost (or benchmark price as determined by the |
| LC001431 - Page 5 of 10 |
1 | PBM). |
2 | (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of |
3 | initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated |
4 | pharmacies in this state that are within the network. Any adjustment must be made to all |
5 | pharmacies within five (5) business days. |
6 | (e) The department of business regulation shall exercise oversight and enforcement of |
7 | this section. |
8 | SECTION 4. Chapter 27-20.1 of the General Laws entitled "Nonprofit Dental Service |
9 | Corporations" is hereby amended by adding thereto the following section: |
10 | 27-20.1-15.1. Pharmacy benefit manager requirements with respect to multi-source |
11 | generic pricing updates to pharmacies. -- (a) Definitions. As used herein: |
12 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
13 | manager will pay toward the cost of a drug; |
14 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
15 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
16 | temporarily unavailable; |
17 | (3) "Therapeutically equivalent" means the equivalent determined by the United States |
18 | Food and Drug Administration. |
19 | (b) "Pharmacy benefit manager (PBM)" means and refers to all requirements with respect |
20 | to multi-source generic pricing updates to pharmacies. |
21 | (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts |
22 | between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting |
23 | representative or agent such as a pharmacy services administrative organization (PSAO): |
24 | (i) Include in such contracts, the basis of the methodology and sources utilized to |
25 | determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any |
26 | successive benchmark pricing formula) of the PBM, update such pricing information on such at |
27 | least every seven (7) calendar days, and establish a reasonable process for the prompt notification |
28 | of such pricing updates to network pharmacies; and |
29 | (ii) Maintain a procedure to eliminate products from the list of drugs subject to such |
30 | pricing or modify MAC rates within three (3) days when such drugs do not meet the standards |
31 | and requirements of this act as set forth in order to remain consistent with pricing changes in the |
32 | marketplace. |
33 | (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source |
34 | generic pricing: |
| LC001431 - Page 6 of 10 |
1 | (1) In order to place a particular prescription drug on a multi-source generic list, the PBM |
2 | must, at a minimum, ensure that: |
3 | (i) The drug have at least three (3) or more nationally available, therapeutically |
4 | equivalent, multiple source generic drugs; |
5 | (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated |
6 | by the Food and Drug Administration; and |
7 | (iii) The product must be available for purchase without limitations by all pharmacies in |
8 | the state from national or regional wholesalers, and not obsolete or temporarily unavailable. |
9 | (d) Standards for pharmacy appeals: |
10 | (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a |
11 | pharmacy's contracting representative or agent such as a pharmacy services administrative |
12 | organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding |
13 | multi-source generic drug pricing. The process shall include the following provisions: |
14 | (i) The right to appeal shall be limited to sixty (60) days following the initial claim; |
15 | (ii) The appeal shall be investigated and resolved within seven (7) days; |
16 | (iii) A telephone number at which a network pharmacy may contact the PBM and speak |
17 | with an individual who is responsible for processing appeals; |
18 | (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify |
19 | the national drug code or UDI of a drug product that may be purchased by contracted pharmacies |
20 | at a price at or below the maximum allowable cost (or benchmark price as determined by the |
21 | PBM). |
22 | (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of |
23 | initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated |
24 | pharmacies in this state that are within the network. Any adjustment must be made to all |
25 | pharmacies within five (5) business days. |
26 | (e) The department of business regulation shall exercise oversight and enforcement of |
27 | this section. |
28 | SECTION 5. Chapter 27-41 of the General Laws entitled "Health Maintenance |
29 | Organizations" is hereby amended by adding thereto the following section: |
30 | 27-41-38.1. Pharmacy benefit manager requirements with respect to multi-source |
31 | generic pricing updates to pharmacies. -- (a) Definitions. As used herein: |
32 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
33 | manager will pay toward the cost of a drug; |
34 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
| LC001431 - Page 7 of 10 |
1 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
2 | temporarily unavailable; |
3 | (3) "Therapeutically equivalent" means the equivalent determined by the United States |
4 | Food and Drug Administration. |
5 | (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect |
6 | to multi-source generic pricing updates to pharmacies. |
7 | (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts |
8 | between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting |
9 | representative or agent such as a pharmacy services administrative organization (PSAO): |
10 | (i) Include in such contracts, the basis of the methodology and sources utilized to |
11 | determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any |
12 | successive benchmark pricing formula) of the PBM, update such pricing information on such at |
13 | least every seven (7) calendar days, and establish a reasonable process for the prompt notification |
14 | of such pricing updates to network pharmacies; and |
15 | (ii) Maintain a procedure to eliminate products from the list of drugs subject to such |
16 | pricing or modify MAC rates within three (3) days when such drugs do not meet the standards |
17 | and requirements of this act as set forth in order to remain consistent with pricing changes in the |
18 | marketplace. |
19 | (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source |
20 | generic pricing: |
21 | (1) In order to place a particular prescription drug on a multi-source generic list, the PBM |
22 | must, at a minimum, ensure that: |
23 | (i) The drug have at least three (3) or more nationally available, therapeutically |
24 | equivalent, multiple source generic drugs; |
25 | (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated |
26 | by the Food and Drug Administration; and |
27 | (iii) The product must be available for purchase without limitations by all pharmacies in |
28 | the state from national or regional wholesalers, and not obsolete or temporarily unavailable. |
29 | (d) Standards for pharmacy appeals: |
30 | (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a |
31 | pharmacy's contracting representative or agent such as a pharmacy services administrative |
32 | organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding |
33 | multi-source generic drug pricing. The process shall include the following provisions: |
34 | (i) The right to appeal shall be limited to sixty (60) days following the initial claim; |
| LC001431 - Page 8 of 10 |
1 | (ii) The appeal shall be investigated and resolved within seven (7) days; |
2 | (iii) A telephone number at which a network pharmacy may contact the PBM and speak |
3 | with an individual who is responsible for processing appeals; |
4 | (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify |
5 | the national drug code or UDI of a drug product that may be purchased by contracted pharmacies |
6 | at a price at or below the maximum allowable cost (or benchmark price as determined by the |
7 | PBM). |
8 | (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of |
9 | initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated |
10 | pharmacies in this state that are within the network. Any adjustment must be made to all |
11 | pharmacies within five (5) business days. |
12 | (e) The department of business regulation shall exercise oversight and enforcement of |
13 | this section. |
14 | SECTION 6. This act shall take effect upon passage. |
======== | |
LC001431 | |
======== | |
| LC001431 - Page 9 of 10 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO INSURANCE - PRESCRIPTION DRUG BENEFITS | |
*** | |
1 | This act would regulate business relationship between pharmacy services providers/group |
2 | health insurers/health service organizations with department of business regulation oversight. |
3 | This act would take effect upon passage. |
======== | |
LC001431 | |
======== | |
| LC001431 - Page 10 of 10 |